Share

Contacts

  • Quotes

    The license agreement with Cipher Pharmaceuticals is a key step in preparing the global launch of MOB-015 and it confirms the significant market potential for our product. Cipher has excellent capabilities to make MOB-015 a success in Canada. We look forward to this exciting partnership and continue to progress commercialization plans in other key markets as we approach Phase 3 results
    Peter Wolpert, Moberg Pharma´s CEO
    We are excited at the prospect of bringing an innovative topical product to market that would be a provide a new safe and effective treatment option for the many Canadians who suffer from onychomycosis. The addition of MOB-015 represents our sixth transaction of the year and demonstrates the continued execution of our growth strategy as we build a pipeline of diversified and differentiated near term products for the Canadian market
    Robert Tessarolo, President and CEO of Cipher
    Completing the enrollment in North America is an important milestone and the result of excellent work from the team. I am very pleased with the progress and the rigorous screening process which increases the probability of strong phase 3 results
    Peter Wolpert, Moberg Pharma’s CEO
    We look forward to welcoming Shaw to Moberg Pharma. He will be joining the company in a highly exciting stage as we approach phase 3-results for MOB-015, where he will be adding valuable experience from the development, launch and commercialization of novel treatments
    Peter Wolpert, CEO Moberg Pharma
    Net revenue for the three key brands in the U.S. grew at record pace, fundamentally outpacing the market and strengthening our leading position in all key categories, while significantly increasing profitability. Meanwhile, MOB-015 studies are progressing according to plan with screening in North America recently completed
    Peter Wolpert, CEO of Moberg Pharma
    Over the past years, Mark Beveridge has played a key role in Moberg Pharma’s finance and transaction teams. It’s a pleasure to welcome Mark to the management team and I look forward to working together with him to continue developing Moberg Pharma’s operations
    Peter Wolpert, CEO of Moberg Pharma
    The year has begun with strong profitability and significant growth for all our key brands and the Phase 3 studies for MOB015 are progressing according to the November 2017 plan. For the first quarter, the company generated revenue growth of 5% adjusted for divested brands, despite currency headwind. In local currency, net revenue for our key brands grew by 12-17%. The EBITDA margin improved from 16% to 24%
    Peter Wolpert, CEO of Moberg Pharma
    This issuance of this patent in the United States is part of our overall strategy to establish a broad portfolio of patent claims to protect our proprietary products and is an important milestone, as we now have granted patents in all territories where we have applied for patent protection.
    Peter Wolpert, Moberg Pharma’s CEO
    With extensive knowledge and experience, Kjell has contributed to the evolution of Moberg Pharma, especially through the development of Kerasal Nail® and MOB-015, where he has been instrumental. I’ve had the pleasure of working with Kjell since 2007 and I am highly grateful for his efforts over the years. I look forward to continuing our collaboration in his role as Senior Advisor to the company
    Peter Wolpert, CEO Moberg Pharma
    We are pleased with the divestment. We have now successfully divested most of our minor brands, enabling us to focus our resources on growing our larger brands
    Peter Wolpert, CEO Moberg Pharma
    Successful marketing and integration of acquisitions has resulted in double-digit growth in retail sales for our three major brands
    Peter Wolpert, CEO of Moberg Pharma
    We are highly pleased with the outcome from NAD and we expect the outcome to further strengthen Kerasal Nails® position and growth prospects in the U.S. market
    Peter Wolpert, CEO of Moberg Pharma AB
    The new organization better reflects the company’s increased focus on the North American market and to progress toward the commercialization of MOB-015, while also enabling synergies in the global sales operations. I would like to thank Martin Ingman for the important work he has done for the company and wish him all the best in the future
    Peter Wolpert, CEO of Moberg Pharma AB
    Replacing the CRO is a key step in the extensive action program that was recently announced. TFS has the capability to accelerate patient recruitment and finalizing the European study. Combined with the new setup in North America, we are confident in achieving strong Phase 3 results within the timeline
    Peter Wolpert, Moberg Pharma’s CEO
    MOB-015 is our most valuable pipeline asset and we see a potential to meet the significant unmet needs of patients suffering from nail fungus. The team is working hard to balance a rigorous screening process while maintaining an aggressive timeline for completing the enrollment. The rigorous screening process is instrumental for the outcome of the Phase 3 studies and to achieve strong claims
    Peter Wolpert, Moberg Pharma’s CEO
    It is a pleasure to welcome Torbjörn to the Management Team at Moberg. I look forward to working together to continue driving the growth of our development programs
    Peter Wolpert, CEO of Moberg Pharma AB
    This issuance of this patent is an important part of our overall strategy to establish a broad portfolio of patent claims to protect our proprietary products
    Peter Wolpert, Moberg Pharma’s CEO
    We are pleased with the agreement with Caret Pharma LLC. which enables us to increase focus on the core Moberg Pharma portfolio. We have now successfully divested both non-core brands included in the acquisition from Prestige Brands, while the acquired strategic brands are developing well
    Peter Wolpert, CEO Moberg Pharma
    Kerasal Nail® reached a market share of 29%, while at the same time, we have expanded distribution for both Dermoplast® and New Skin®. Enrolment for the MOB-015 study has taken longer than expected but is accelerating after corrective measures have been implemented
    Peter Wolpert, CEO Moberg Pharma
    The successful results from patients with nail psoriasis, and for the study as a whole, make a stronger selling point for Kerasal Nail®/ Emtrix®, something which is of great importance for future efforts in all markets
    Peter Wolpert, CEO of Moberg Pharma
    This is our most recent acquisition and we are pleased that the integration is progressing according to plan. The distribution gains provide excellent opportunities to build on the brand equity of Dermoplast® in the years to come
    Jeff Vernimb, GM of Moberg Pharma North America
    We are excited about the prospects for Zanmira Nail® in Japan, which has the potential to become a major market for Moberg Pharma. We look forward to the continued collaboration with CMIC in Japan, as well as with Menarini in the other markets of the Asia-Pacific region
    Peter Wolpert, CEO of Moberg Pharma
    The divestment is made for personal financial reasons and I don’t intend to sell additional shares. I have great faith in the prospects for Moberg Pharma and I look forward to continuing to build the company
    Peter Wolpert, CEO of Moberg Pharma
    We see excellent opportunities to build on the brand equity of New Skin®. This a market leading brand with exciting prospects for growth, as shown with the increased distribution
    Jeff Vernimb, GM of Moberg Pharma North America
    We highly appreciate the support provided by our bondholders and the large interest for this tap issue. As a result, the issue has been placed at a premium to the nominal amount and we have secured the capital needed to complete the acquisition of DermoPlast®. From January 2017, DermoPlast® is expected to contribute significantly to our profitability and operative cash flow
    Peter Wolpert, CEO of Moberg Pharma
    I am proud to announce the acquisition of DermoPlast®. After thorough evaluation and diligence I am very pleased that we have now secured financing to be able to complete this important acquisition for Moberg Pharma. The transaction is expected to contribute positively to our sales and profitability and contribute to our long-term financial target to deliver profitable growth and an EBITDA-margin of 25 percent
    Peter Wolpert, CEO of Moberg Pharma
    The Board of Directors of Moberg Pharma is very pleased with the acquisition of DermoPlast®. Through the acquisition, the company strengthens its portfolio of strategic brands – DermoPlast® fits perfectly into the company's focus on topical products. We can also fully utilize the existing organization and sales channels in the U.S. After the acquisitions, the company now has three major strategic brands – Kerasal Nail®, DermoPlast® and New Skin® – which increases the diversification and thus strengthens the company. The focus over the coming year is to successfully integrate acquisitions and to strengthen the positioning of our portfolio and to continue to create value through the advancement of our development pipeline
    Thomas Eklund, chairman of Moberg Pharma
    The opportunity to acquire DermoPlast® is very attractive. The acquisition is in line with our strategy and leverages our existing infrastructure and sales channels in the U.S. in an excellent way. DermoPlast® brings increased economies of scale and complements our portfolio with a strong and profitable dermatology brand. We are very pleased with the opportunity to complete this transaction, which is expected to contribute positively to both our sales and profitability and thereby to our long term financial target to deliver profitable growth and an EBITDA margin of 25 per cent
    Peter Wolpert, CEO of Moberg Pharma
    We appreciate the increased flexibility which our bondholders have granted the company and hence enhanced our possibilities to optimally finance accretive acquisitions
    Peter Wolpert, Moberg Pharma’s CEO
    We are pleased with the agreement with Strides which enables us to further focus on our strategic assets and M&A activities
    Peter Wolpert, CEO Moberg Pharma
    We had very positive momentum in Q3. The team has already now delivered on all major milestones for 2016
    Peter Wolpert, CEO of Moberg Pharma
    This patent provides Moberg with important intellectual property protection for BUPI, our lozenge formulation of bupivacaine for pain management of oral mucositis in cancer patients
    Peter Wolpert, CEO of Moberg Pharma
    This issuance of this patent is an important milestone for the BUPI development program and part of our overall strategy to establish a broad portfolio of patent claims to protect our proprietary products.
    Peter Wolpert, CEO of Moberg Pharma
    The start of the patient enrollment in the Phase 3 program for MOB-015 is a major milestone for Moberg Pharma
    Peter Wolpert, CEO of Moberg Pharma
    Our long-term vision is to become a global leader in onychomycosis and we believe that MOB-015 has the potential to establish a new standard of care. The Phase 3 studies have been designed to support registration in North America, Europe and other major markets
    Peter Wolpert, CEO of Moberg Pharma
    This is a significant step forward in the further development of MOB-015. We are committed in our pursuit to bring an efficacious and safe topical treatment in the form of MOB-015 to patients suffering from nail fungus
    Kjell Rensfeldt, VP Research and Development of Moberg Pharma AB
    We are pleased with the significant interest from Swedish and other Nordic investors. Our maintained activity in the corporate bond market strengthens our capacity to raise non-dilutive financing and we are very pleased to have been able to issue these subsequent bonds at a premium to the nominal amount, despite recent market turbulence
    Peter Wolpert, CEO of Moberg Pharma AB
    This acquisition is in line with our strategy to add critical mass to Moberg’s U.S. operations as well as a leading topical brand to our core dermatology franchise. This transaction is an excellent use of the proceeds from the bond loan issue earlier this year and the funds released in the recent divestment of non-core brands to Strides Pharma Inc. The acquired brands will immediately contribute significantly to our sales and earnings and also to our long term financial goal of delivering profitable growth and an EBITDA margin of 25%. In three recent transactions, we have established relationships with major OTC players - Bayer, Chattem and now Prestige - which also will facilitate future transactions
    Peter Wolpert, CEO of Moberg Pharma AB
    We see excellent opportunities to build on the brand equity of New Skin. This a market leading brand with exciting prospects for growth. We will leverage our Innovation Engine to further strengthen the future value proposition of this brand as well as Fiber Choice and PediaCare to consumers and retailers
    Jeff Vernimb, GM of Moberg Pharma North America
    We are very pleased with the progress of the global launch of Kerasal Nail/Emtrix. The recent and immediate success achieved in important markets like Japan and Taiwan is indicative of the significant potential of Kerasal Nail/Emtrix in this dynamic region. We expect the region to become an even more important contributor to revenues and earnings
    Martin Ingman, VP Sales & Marketing Moberg Pharma AB
    The overwhelmingly positive consumer response to the brand repositioning and new marketing campaign launched in early 2016 confirms our hypothesis that the clinically proven visible difference that Kerasal Nail provides is a key benefit that consumers value highly. Kerasal Nail continues to be an important growth driver in the OTC segment with a meaningful message able to breakthrough and be heard
    Jeff Vernimb, GM of Moberg Pharma North America.
    These patents are exceptionally important to Moberg since they secure IP rights for MOB-015 until at least 2032 in various markets worldwide where we plan to sell or license this product, once approved. They represent a strong addition to our portfolio which now includes 12 issued patents and 27 pending patent applications worldwide in four different patent families
    Peter Wolpert, CEO of Moberg Pharma AB
    We are thrilled by the prospect of developing BUPI through Phase III and subsequently making the product available to patients in great need of improved pain relief. The de-risked strategy significantly reduces our investment requirement, while allowing us to retain commercial rights in all major territories as well as rights to data from the two Phase III studies. This strategy will enable Moberg Pharma to build substantial value in the BUPI asset for its shareholders
    Peter Wolpert, CEO of Moberg Pharma AB
    We are excited to enter this collaboration with Cadila Pharmaceuticals and to leverage our combined innovation capabilities as well as Cadila’s clinical, manufacturing and commercialization capabilities in India. Establishing innovative partnership models supports Moberg’s commitment to bringing novel treatments to patients in underserved niches
    Peter Wolpert, CEO of Moberg Pharma AB
    In line with our philosophy to bring innovative solutions to unmet medical needs, we are delighted to partner with Moberg Pharma on BUPI to bring more efficacious pain management to patients with oral mucositis, a condition with high prevalence in India
    Dr. Rajiv I. Modi, Chairman and Managing Director, Cadila Pharmaceuticals Ltd., India
    We are pleased with the agreement with Strides which enables us to further focus on our strategic assets and M&A activities. The transaction also results in a capital gain for our shareholders
    Peter Wolpert, CEO Moberg Pharma
    We are pleased with the large interest among Swedish and Nordic investors for the bond loan, despite challenging market conditions. The access to the corporate bond market and non-dilutive financing strengthens our financial position further and is an important step in the financing of the company’s growth and acquisition strategy
    Peter Wolpert, CEO Moberg Pharma
    Moberg Pharma has in five years grown from zero to close to SEK 300 million in revenue and created a profitable business. We are in a position to strengthen the company and create considerable value for our shareholders. Short-term, we make significant investments while maintaining our long-term financial goal of achieving an EBITDA margin of at least 25 percent
    Peter Wolpert, CEO Moberg Pharma
    This study shows that BUPI provided additional pain reduction to levels below VAS 40 in a patient population for which it is difficult to achieve adequate pain relief. Developing a new formulation of bupivacaine, intended for self-administration at home, requires a thorough evaluation of the safety profile of the product. Moberg Pharma will now proceed with in-depth analyses of all other data collected in this study, in order to guide further clinical development of BUPI
    Kjell Rensfeldt, VP Research and Development at Moberg Pharma
    In total, 32 patients meeting the amended inclusion criteria have now completed the study. We expect to announce topline data in January
    Kjell Rensfeldt, VP R&D of Moberg Pharma AB
    Pick a time period -
    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media